CRSP Quote, Financials, Valuation and Earnings

Novartis AG has a net margin of -106.6% compared to CRISPR Therapeutics AG's net margin of 26.48%. CRISPR Therapeutics AG's return on equity of -18.65% beat Novartis AG's return on equity of 30.96%.

CRISPR Therapeutics AG has a consensus price target of $81.92, signalling upside risk potential of 129.97%. On the other hand Novartis AG has an analysts' consensus of $112.37 which suggests that it could grow by 3.38%. Given that CRISPR Therapeutics AG has higher upside potential than Novartis AG, analysts believe CRISPR Therapeutics AG is more attractive than Novartis AG.

CRISPR Therapeutics AG has a beta of 1.877, which suggesting that the stock is 87.729% more volatile than S&P 500. In comparison Novartis AG has a beta of 0.603, suggesting its less volatile than the S&P 500 by 39.726%.

CRISPR Therapeutics AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novartis AG offers a yield of 3.67% to investors and pays a quarterly dividend of $3.99 per share. CRISPR Therapeutics AG pays -- of its earnings as a dividend. Novartis AG pays out 63.85% of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

CRISPR Therapeutics AG quarterly revenues are $35M, which are smaller than Novartis AG quarterly revenues of $13.6B. CRISPR Therapeutics AG's net income of -$136M is lower than Novartis AG's net income of $3.6B. Notably, CRISPR Therapeutics AG's price-to-earnings ratio is -- while Novartis AG's PE ratio is 17.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CRISPR Therapeutics AG is -- versus 4.12x for Novartis AG. Usually stocks with elevated PS ratios are considered overvalued.

Roche Holding AG has a net margin of -106.6% compared to CRISPR Therapeutics AG's net margin of --. CRISPR Therapeutics AG's return on equity of -18.65% beat Roche Holding AG's return on equity of 23.8%.

CRISPR Therapeutics AG has a consensus price target of $81.92, signalling upside risk potential of 129.97%. On the other hand Roche Holding AG has an analysts' consensus of $46.42 which suggests that it could grow by 20.97%. Given that CRISPR Therapeutics AG has higher upside potential than Roche Holding AG, analysts believe CRISPR Therapeutics AG is more attractive than Roche Holding AG.

CRISPR Therapeutics AG has a beta of 1.877, which suggesting that the stock is 87.729% more volatile than S&P 500. In comparison Roche Holding AG has a beta of 0.467, suggesting its less volatile than the S&P 500 by 53.264%.

CRISPR Therapeutics AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Roche Holding AG offers a yield of 3.62% to investors and pays a quarterly dividend of $1.39 per share. CRISPR Therapeutics AG pays -- of its earnings as a dividend. Roche Holding AG pays out 92.43% of its earnings as a dividend. Roche Holding AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

CRISPR Therapeutics AG quarterly revenues are $35M, which are larger than Roche Holding AG quarterly revenues of --. CRISPR Therapeutics AG's net income of -$136M is higher than Roche Holding AG's net income of --. Notably, CRISPR Therapeutics AG's price-to-earnings ratio is -- while Roche Holding AG's PE ratio is 26.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CRISPR Therapeutics AG is -- versus 3.52x for Roche Holding AG. Usually stocks with elevated PS ratios are considered overvalued.

Sandoz Group AG has a net margin of -106.6% compared to CRISPR Therapeutics AG's net margin of -39.83%. CRISPR Therapeutics AG's return on equity of -18.65% beat Sandoz Group AG's return on equity of --.

CRISPR Therapeutics AG has a consensus price target of $81.92, signalling upside risk potential of 129.97%. On the other hand Sandoz Group AG has an analysts' consensus of -- which suggests that it could fall by --. Given that CRISPR Therapeutics AG has higher upside potential than Sandoz Group AG, analysts believe CRISPR Therapeutics AG is more attractive than Sandoz Group AG.

CRISPR Therapeutics AG has a beta of 1.877, which suggesting that the stock is 87.729% more volatile than S&P 500. In comparison Sandoz Group AG has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

CRISPR Therapeutics AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sandoz Group AG offers a yield of 1.48% to investors and pays a quarterly dividend of $0.67 per share. CRISPR Therapeutics AG pays -- of its earnings as a dividend. Sandoz Group AG pays out -- of its earnings as a dividend.

CRISPR Therapeutics AG quarterly revenues are $35M, which are smaller than Sandoz Group AG quarterly revenues of $74.4M. CRISPR Therapeutics AG's net income of -$136M is lower than Sandoz Group AG's net income of -$29.6M. Notably, CRISPR Therapeutics AG's price-to-earnings ratio is -- while Sandoz Group AG's PE ratio is 26.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CRISPR Therapeutics AG is -- versus 1.91x for Sandoz Group AG. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of -106.6% compared to CRISPR Therapeutics AG's net margin of 23.33%. CRISPR Therapeutics AG's return on equity of -18.65% beat Vertex Pharmaceuticals's return on equity of -6.04%.

CRISPR Therapeutics AG has a consensus price target of $81.92, signalling upside risk potential of 129.97%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $500.30 which suggests that it could grow by 17.72%. Given that CRISPR Therapeutics AG has higher upside potential than Vertex Pharmaceuticals, analysts believe CRISPR Therapeutics AG is more attractive than Vertex Pharmaceuticals.

CRISPR Therapeutics AG has a beta of 1.877, which suggesting that the stock is 87.729% more volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.511, suggesting its less volatile than the S&P 500 by 48.928%.

CRISPR Therapeutics AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CRISPR Therapeutics AG pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

CRISPR Therapeutics AG quarterly revenues are $35M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. CRISPR Therapeutics AG's net income of -$136M is lower than Vertex Pharmaceuticals's net income of $646.3M. Notably, CRISPR Therapeutics AG's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CRISPR Therapeutics AG is -- versus 9.92x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.